Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Council on Early-morning, Late-night Drug Sales Holds 1st Meeting
November 3, 2003
-
ARCHIVE BUSINESS NEWS IN BRIEF
November 3, 2003
-
ARCHIVE Safety, Convenience Are Both Rights of Consumers: JACDS
November 3, 2003
-
ARCHIVE Drug Cost Ratio Hits Record Low, 21.6% in 2002
November 3, 2003
-
ARCHIVE Victims of Drug-induced Health Damage Firmly Opposed to Sales Deregulation
November 3, 2003
-
ARCHIVE Drug Production Value Fell 0.2% in 2002
November 3, 2003
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
November 3, 2003
-
ARCHIVE HPB, HSB Notify Prefectures on Expected Supplies of Influenza Drugs
November 3, 2003
-
COMMENTARY <Special Contribution>
November 3, 2003
-
ARCHIVE BUSINESS NEWS IN BRIEF
October 27, 2003
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
October 27, 2003
-
ARCHIVE BULLETIN
October 27, 2003
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
October 27, 2003
-
ARCHIVE WEBSITE NEWS
October 27, 2003
-
ARCHIVE Most GE Houses Forecast Growth in FY2003: EPMA Survey
October 27, 2003
-
ARCHIVE <Special Contribution>
October 27, 2003
-
ARCHIVE Import Approval for Evista, Precedex Recommended
October 27, 2003
-
ARCHIVE Pricing of Long-listed Drugs Discussed by Chuikyo Subpanel
October 27, 2003
-
ARCHIVE Korosho to Widen Selection Criteria for Priority NDA Review
October 27, 2003
-
ARCHIVE REGULATORY NEWS IN BRIEF
October 27, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…